Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Levamisole in First Flare Steroid Sensitive Nephrotic Syndrome
NCT02818738Phase 3Completed
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Sep 2017
- Primary completion
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Idiopathic nephrotic syndrome (INS) comparing Levamisole with Placebo (2 arms). Primary endpoint: Percentage of patients still in remission at 12 months after first flare of INS. Started Sep 2017; status: completed.
02
Drugs
levamisole
03
Conditions
Idiopathic nephrotic syndrome (INS)
Beyond the preview
Go deeper on NCT02818738.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02818738.